Business
COEGIN: First commercial revenues achieved, portfolio expanded, and liquidity strengthened via share issue
COEGIN: First commercial revenues achieved, portfolio expanded, and liquidity strengthened via share issue
About this update from Coegin Pharma Ab
Transitioned to commercial scale-up with first revenues from Follicopeptide Gel Serum and expanded the product portfolio. Liquidity was strengthened by a SEK 12.1 million share issue, while operating losses narrowed year-over-year. Risks remain around financing and commercialization progress.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.